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Background
It is a known fact that cancer risk is influenced by
both environmental and genetic factors. Parameters
such as the kind and site of the tumour and family hi-
story depend on the proportion between both and the
population determines to a great extent the characte-
ristics of the genetic background. Here we focus on
breast cancer in the Polish population.
Despite complex population dynamics in the last
centuries, the Poles seem to be surprisingly homoge-
neous in their genetics. A sequence-based screening
of BRCA1 positive patients showed just 9 polymorphi-
sms of BRCA1, where 91% of individuals shared just
3 common founder mutations [1]. The result is consi-
stent with other Slavic countries [2-4]. In contrast, a si-
milar screening in neighbouring Germany revealed 77
distinct BRCA1 mutations, 18 of them shared by 68%
of BRCA1 positive patients [5].
Highly penetrating mutations, such as those of
BRCA1, are mostly detected in conspicuous family ag-
gregations via genetic linkage studies. Therefore, they
may be detected with the help of just a few families even
in heterogeneous populations. However, the probability
of finding a new highly penetrating gene for the Polish
population seems rather low; mutations of BRCA1 and
BRCA2 already cover ~70% of cases of strong familial
aggregations of breast and ovarian cancers [1]. The ad-
vantage of genetically homogeneous populations relies
instead on the increased power of finding medium- and
low-risk markers via large association studies that would
otherwise be blurred in more complex populations.
Results
To date several variants of 6 genes have been de-
monstrated to significantly increase breast cancer risk
in the Polish population: BRCA1, BRCA2, CHEK2,
NBS1, NOD2, P16 [1, 6-9]. They actually cover
~25% of early onset (<50 yrs) breast cancer cases
(n=3000). Current investigations extend those 6 ge-
nes up to 9 (data in preparation) (Fig. 1). One of
them, represented as X2, includes a common variant
that improves the total coverage up to 80% in a pre-
Fig. 1. Frequency of different genes with variants associated with breast
cancer as covering a population of 3000 early onset (<50 yrs) breast
cancer patients. Genes represented as X1-X3 are still subject of study
and their values refer to estimations from preliminary data. Most of
the genes represented include several disease-associated variants.
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liminary analysis: 700 cases out of 850 showed at
least one disease-associated variant of the 9 analy-
sed genes (Fig. 2).
Those values should drop for cases with onset at
older ages as the cumulative exposure to external car-
cinogenic agents increases. Nevertheless, in familial
aggregations of breast and ovarian cancer that per-
centage is expected to be higher since just BRCA1 and
BRCA2 account already for almost 70% of cases. Both
analyses have still to be performed.
Conclusions
The Polish population appears to be a useful gro-
up for detecting low-risk markers of cancer. It is large
(~40m) and homogeneous enough to reach the sta-
tistical power necessary to detect small but still signi-
ficant differences in cancer risk. Our actual knowled-
ge of disease-associated genetic factors present in
breast cancer cases is ~70% for familial aggregations
and ~80% for early onset consecutive cases. Thanks
to the parallel growth of the network country-wide for
sample and data exchange and the genetic variants
under analysis, we expect to approach 100% in the
near future.
But even in such a scenario, the detection of a sin-
gle predisposing genetic factor does not exclude the
presence of additional ones. In fact, the current mo-
del predicts that the interplay between several genetic
factors of low penetrance when analysed separately
may increase the risk (either additively or synergically)
to values comparable to much more penetrating ones
(Fig. 3) [10]. Therefore, the search for new low-risk
markers should continue even beyond the theoretical
100% of coverage, and bioinformatic analyses of the
interplay among these factors should improve their ap-
plication in clinical practice. 
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Fig. 2. Time sequence of the growth of the sample database (dashed
line) in number of patients (note: the number of genotyped samples is
actually 3500) and the improvement of the coverage of disease-
associated genetic factors in the same population (continuous line). The
percentage of coverage is based on estimations for different numbers
of patients depending on the specific genes involved: 3000 patients for
BRCA1, BRCA2, CHEK2, NBS1, NOD2 and P16; and 850 patients
for those genes and the ones referred as X1, X2 and X3 (currently under
study). The approximately onset of systematic analyses for the respective
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